PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28093224-1 2017 The Arg/Arg homozygosity at codon 16 of the beta-2-adrenoreceptor (ADRB2) gene has been thought to predispose asthma patients to a poorer therapeutic response to beta-2-mimetics, or to worse control of the disease. Arginine 4-7 adrenoceptor beta 2 Homo sapiens 44-65 29061864-1 2017 The predominating beta-adrenergic receptor subtype expressed on human alveolar tissue is the beta2AR The homozygous arginine (Arg16Arg) single-nucleotide polymorphism (SNP) at codon 16 of the beta2AR gene has been associated with abnormal beta2AR function accompanied by decreased resting alveolar-capillary membrane gas-transfer in certain healthy adults. Arginine 116-124 adrenoceptor beta 2 Homo sapiens 93-100 29061864-1 2017 The predominating beta-adrenergic receptor subtype expressed on human alveolar tissue is the beta2AR The homozygous arginine (Arg16Arg) single-nucleotide polymorphism (SNP) at codon 16 of the beta2AR gene has been associated with abnormal beta2AR function accompanied by decreased resting alveolar-capillary membrane gas-transfer in certain healthy adults. Arginine 116-124 adrenoceptor beta 2 Homo sapiens 192-199 29061864-1 2017 The predominating beta-adrenergic receptor subtype expressed on human alveolar tissue is the beta2AR The homozygous arginine (Arg16Arg) single-nucleotide polymorphism (SNP) at codon 16 of the beta2AR gene has been associated with abnormal beta2AR function accompanied by decreased resting alveolar-capillary membrane gas-transfer in certain healthy adults. Arginine 116-124 adrenoceptor beta 2 Homo sapiens 192-199 30855197-10 2019 Presence of Arg/Gly or Gly/Gly genotypes in position 16 of ADRB2 was significantly associated to a worse BD response (post-BD FEV1: 108.68% +- 15.62% in Arg/Arg vs. 101.86% +- 14.03% in Arg/Gly or Gly/Gly patients, p = 0.02). Arginine 12-15 adrenoceptor beta 2 Homo sapiens 59-64 30855197-10 2019 Presence of Arg/Gly or Gly/Gly genotypes in position 16 of ADRB2 was significantly associated to a worse BD response (post-BD FEV1: 108.68% +- 15.62% in Arg/Arg vs. 101.86% +- 14.03% in Arg/Gly or Gly/Gly patients, p = 0.02). Arginine 153-156 adrenoceptor beta 2 Homo sapiens 59-64 30855197-10 2019 Presence of Arg/Gly or Gly/Gly genotypes in position 16 of ADRB2 was significantly associated to a worse BD response (post-BD FEV1: 108.68% +- 15.62% in Arg/Arg vs. 101.86% +- 14.03% in Arg/Gly or Gly/Gly patients, p = 0.02). Arginine 153-156 adrenoceptor beta 2 Homo sapiens 59-64 30855197-10 2019 Presence of Arg/Gly or Gly/Gly genotypes in position 16 of ADRB2 was significantly associated to a worse BD response (post-BD FEV1: 108.68% +- 15.62% in Arg/Arg vs. 101.86% +- 14.03% in Arg/Gly or Gly/Gly patients, p = 0.02). Arginine 153-156 adrenoceptor beta 2 Homo sapiens 59-64 30267546-8 2018 Twenty-eight recreationally active men (mean +- SD 23.1 +- 1.3 years of age) were genotyped for Arg16Gly polymorphisms of beta2 -AR as arginine homozygous (ArgArg; n = 5), glycine homozygous (GlyGly; n = 11) or arginine-glycine heterozygous (ArgGly; n = 12). Arginine 135-143 adrenoceptor beta 2 Homo sapiens 122-131 29658513-5 2018 The presence of heterozygous Arg-Gly and Gln-Glu gives a better response to drug therapy than the presence of Gly-Gly and Glu-Glu genotypes at codons 16 and 27.ConclusionPolymorphism of beta2AR at codons 16 and 27 correlates with asthma severity and response to treatment in asthmatic children. Arginine 29-32 adrenoceptor beta 2 Homo sapiens 186-193 28093224-1 2017 The Arg/Arg homozygosity at codon 16 of the beta-2-adrenoreceptor (ADRB2) gene has been thought to predispose asthma patients to a poorer therapeutic response to beta-2-mimetics, or to worse control of the disease. Arginine 4-7 adrenoceptor beta 2 Homo sapiens 67-72 28093224-1 2017 The Arg/Arg homozygosity at codon 16 of the beta-2-adrenoreceptor (ADRB2) gene has been thought to predispose asthma patients to a poorer therapeutic response to beta-2-mimetics, or to worse control of the disease. Arginine 8-11 adrenoceptor beta 2 Homo sapiens 44-65 28093224-1 2017 The Arg/Arg homozygosity at codon 16 of the beta-2-adrenoreceptor (ADRB2) gene has been thought to predispose asthma patients to a poorer therapeutic response to beta-2-mimetics, or to worse control of the disease. Arginine 8-11 adrenoceptor beta 2 Homo sapiens 67-72 28093224-6 2017 Arg/Arg homozygotes at codon 16 required at least two courses of antibiotic therapy administered as a result of a lower respiratory tract infection significantly more frequently than carriers of other polymorphic variants of the ADRB2. Arginine 0-3 adrenoceptor beta 2 Homo sapiens 229-234 28093224-6 2017 Arg/Arg homozygotes at codon 16 required at least two courses of antibiotic therapy administered as a result of a lower respiratory tract infection significantly more frequently than carriers of other polymorphic variants of the ADRB2. Arginine 4-7 adrenoceptor beta 2 Homo sapiens 229-234 28093224-9 2017 These data suggested that Arg/Arg homozygosity at codon 16 of the ADRB2 gene predisposes patients to a clinically more severe course of COPD. Arginine 26-29 adrenoceptor beta 2 Homo sapiens 66-71 28093224-9 2017 These data suggested that Arg/Arg homozygosity at codon 16 of the ADRB2 gene predisposes patients to a clinically more severe course of COPD. Arginine 30-33 adrenoceptor beta 2 Homo sapiens 66-71 27027728-6 2016 Four selected polymorphisms were determined: beta1 -adrenergic receptor polymorphisms Ser(49) Gly and Arg(389) Gly and beta2 -adrenergic receptor polymorphisms Arg(16) Gly and Gln(27) Glu. Arginine 160-163 adrenoceptor beta 2 Homo sapiens 119-145 27050801-0 2016 Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma. Arginine 14-17 adrenoceptor beta 2 Homo sapiens 35-39 27050801-8 2016 CONCLUSIONS: Withdrawal of LABA therapy in asthmatics with the Arg/Arg genotype at the 16th amino acid position of B2AR did not lead to significant improvement in AM PEFR. Arginine 63-66 adrenoceptor beta 2 Homo sapiens 115-119 27050801-8 2016 CONCLUSIONS: Withdrawal of LABA therapy in asthmatics with the Arg/Arg genotype at the 16th amino acid position of B2AR did not lead to significant improvement in AM PEFR. Arginine 67-70 adrenoceptor beta 2 Homo sapiens 115-119 26774659-1 2016 BACKGROUND: The Gly-to-Arg substitution at the 16 position (rs1042713) in the beta2-adrenoceptor gene (ADRB2) is associated with enhanced downregulation and uncoupling of beta2-receptors. Arginine 23-26 adrenoceptor beta 2 Homo sapiens 78-96 26774659-1 2016 BACKGROUND: The Gly-to-Arg substitution at the 16 position (rs1042713) in the beta2-adrenoceptor gene (ADRB2) is associated with enhanced downregulation and uncoupling of beta2-receptors. Arginine 23-26 adrenoceptor beta 2 Homo sapiens 103-108 24201779-8 2014 Conversely, an increased risk was observed for the glycine/arginine or arginine/arginine genotype of the adrenoceptor beta2, surface (ADRB2) gene rs1042713 as compared with the glycine/glycine genotype (odds ratio, 1.52 [95% confidence interval, 1.01-2.31]). Arginine 59-67 adrenoceptor beta 2 Homo sapiens 105-132 27421901-0 2016 The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma. Arginine 4-7 adrenoceptor beta 2 Homo sapiens 32-37 27421901-0 2016 The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma. Arginine 8-11 adrenoceptor beta 2 Homo sapiens 32-37 26071206-13 2015 In a South Indian population, the ADRB2 Arg/Gly may not form a susceptible variant to develop asthma nor can be a standard predictive marker to bronchodilator response; nevertheless, the patterns in asthma severity can be predicted by analyzing this variant. Arginine 40-43 adrenoceptor beta 2 Homo sapiens 34-39 24201779-8 2014 Conversely, an increased risk was observed for the glycine/arginine or arginine/arginine genotype of the adrenoceptor beta2, surface (ADRB2) gene rs1042713 as compared with the glycine/glycine genotype (odds ratio, 1.52 [95% confidence interval, 1.01-2.31]). Arginine 59-67 adrenoceptor beta 2 Homo sapiens 134-139 24201779-8 2014 Conversely, an increased risk was observed for the glycine/arginine or arginine/arginine genotype of the adrenoceptor beta2, surface (ADRB2) gene rs1042713 as compared with the glycine/glycine genotype (odds ratio, 1.52 [95% confidence interval, 1.01-2.31]). Arginine 71-79 adrenoceptor beta 2 Homo sapiens 105-132 24201779-8 2014 Conversely, an increased risk was observed for the glycine/arginine or arginine/arginine genotype of the adrenoceptor beta2, surface (ADRB2) gene rs1042713 as compared with the glycine/glycine genotype (odds ratio, 1.52 [95% confidence interval, 1.01-2.31]). Arginine 71-79 adrenoceptor beta 2 Homo sapiens 134-139 24201779-8 2014 Conversely, an increased risk was observed for the glycine/arginine or arginine/arginine genotype of the adrenoceptor beta2, surface (ADRB2) gene rs1042713 as compared with the glycine/glycine genotype (odds ratio, 1.52 [95% confidence interval, 1.01-2.31]). Arginine 71-79 adrenoceptor beta 2 Homo sapiens 105-132 24201779-8 2014 Conversely, an increased risk was observed for the glycine/arginine or arginine/arginine genotype of the adrenoceptor beta2, surface (ADRB2) gene rs1042713 as compared with the glycine/glycine genotype (odds ratio, 1.52 [95% confidence interval, 1.01-2.31]). Arginine 71-79 adrenoceptor beta 2 Homo sapiens 134-139 23056045-0 2012 Arginine 16 Glycine Polymorphism in beta2-Adrenergic Receptor Gene is Associated with Obesity, Hyperlipidemia, Hyperleptinemia, and Insulin Resistance in Saudis. Arginine 0-8 adrenoceptor beta 2 Homo sapiens 36-61 23613100-11 2013 Pharmacogenomic studies have shown that patients with polymorphisms of the beta2-adrenoreceptor (ADRB2; 16 Arg/Arg and 16 Arg/Gly) are particularly responsive to treatment with tiotropium. Arginine 107-110 adrenoceptor beta 2 Homo sapiens 75-95 23613100-11 2013 Pharmacogenomic studies have shown that patients with polymorphisms of the beta2-adrenoreceptor (ADRB2; 16 Arg/Arg and 16 Arg/Gly) are particularly responsive to treatment with tiotropium. Arginine 107-110 adrenoceptor beta 2 Homo sapiens 97-102 23613100-11 2013 Pharmacogenomic studies have shown that patients with polymorphisms of the beta2-adrenoreceptor (ADRB2; 16 Arg/Arg and 16 Arg/Gly) are particularly responsive to treatment with tiotropium. Arginine 111-114 adrenoceptor beta 2 Homo sapiens 75-95 23613100-11 2013 Pharmacogenomic studies have shown that patients with polymorphisms of the beta2-adrenoreceptor (ADRB2; 16 Arg/Arg and 16 Arg/Gly) are particularly responsive to treatment with tiotropium. Arginine 111-114 adrenoceptor beta 2 Homo sapiens 97-102 23613100-11 2013 Pharmacogenomic studies have shown that patients with polymorphisms of the beta2-adrenoreceptor (ADRB2; 16 Arg/Arg and 16 Arg/Gly) are particularly responsive to treatment with tiotropium. Arginine 111-114 adrenoceptor beta 2 Homo sapiens 75-95 23613100-11 2013 Pharmacogenomic studies have shown that patients with polymorphisms of the beta2-adrenoreceptor (ADRB2; 16 Arg/Arg and 16 Arg/Gly) are particularly responsive to treatment with tiotropium. Arginine 111-114 adrenoceptor beta 2 Homo sapiens 97-102 23484198-4 2013 Arg-Arg in position 16 in ADRB2 receptors determines the developmental risk of side effects, while Gly-Gly in the same codon determines tolerance to beta2-adrenoceptor agonists and is associated with more severe course of myasthenia and resistance to beta2-adrenoceptor agonists treatment with ADRB2 agonists. Arginine 0-3 adrenoceptor beta 2 Homo sapiens 26-31 23484198-4 2013 Arg-Arg in position 16 in ADRB2 receptors determines the developmental risk of side effects, while Gly-Gly in the same codon determines tolerance to beta2-adrenoceptor agonists and is associated with more severe course of myasthenia and resistance to beta2-adrenoceptor agonists treatment with ADRB2 agonists. Arginine 4-7 adrenoceptor beta 2 Homo sapiens 26-31 23964556-5 2013 CONCLUSIONS: Our study demonstrated that nocturnal asthma was associated with ADRB2 Arg/Gly polymorphisms but not with ADRB2 Gln/Glu polymorphisms. Arginine 84-87 adrenoceptor beta 2 Homo sapiens 78-83 22883364-7 2012 Children exposed to mildewy odor with ADRB2 Arg/Arg genotype were associated with being awakened at night due to wheezing (OR=1.95, 95% CI, 1.14-3.36), compared to those without exposure and with the ADRB2 Gly allele. Arginine 44-47 adrenoceptor beta 2 Homo sapiens 38-43 22883364-7 2012 Children exposed to mildewy odor with ADRB2 Arg/Arg genotype were associated with being awakened at night due to wheezing (OR=1.95, 95% CI, 1.14-3.36), compared to those without exposure and with the ADRB2 Gly allele. Arginine 44-47 adrenoceptor beta 2 Homo sapiens 200-205 22883364-7 2012 Children exposed to mildewy odor with ADRB2 Arg/Arg genotype were associated with being awakened at night due to wheezing (OR=1.95, 95% CI, 1.14-3.36), compared to those without exposure and with the ADRB2 Gly allele. Arginine 48-51 adrenoceptor beta 2 Homo sapiens 38-43 22883364-7 2012 Children exposed to mildewy odor with ADRB2 Arg/Arg genotype were associated with being awakened at night due to wheezing (OR=1.95, 95% CI, 1.14-3.36), compared to those without exposure and with the ADRB2 Gly allele. Arginine 48-51 adrenoceptor beta 2 Homo sapiens 200-205 22883364-9 2012 Frequency and degree of home dampness were also associated with the prevalence of asthma and selected indicators of severity of asthma, in an exposure-response manner among children with ADRB2 Arg/Arg genotype. Arginine 193-196 adrenoceptor beta 2 Homo sapiens 187-192 22883364-9 2012 Frequency and degree of home dampness were also associated with the prevalence of asthma and selected indicators of severity of asthma, in an exposure-response manner among children with ADRB2 Arg/Arg genotype. Arginine 197-200 adrenoceptor beta 2 Homo sapiens 187-192 22883364-10 2012 CONCLUSIONS: Home dampness prevention is one of the important steps of asthma control, especially in children carrying ADRB2 Arg/Arg genotypes. Arginine 125-128 adrenoceptor beta 2 Homo sapiens 119-124 22843684-0 2012 The arginine of the DRY motif in transmembrane segment III functions as a balancing micro-switch in the activation of the beta2-adrenergic receptor. Arginine 4-12 adrenoceptor beta 2 Homo sapiens 122-147 23548524-4 2013 METHODS: We conducted a retrospective analysis of the effects of ADRB2 haplotypes at position 16 (Gly/Arg) and 27(Gln/Glu) in 449 patients with a physician diagnosis of asthma who were responsive to methacholine (ie, provocation concentration that caused a decrease in forced expiratory volume in 1 second [FEV(1)] of 20% [PC(20)], <8 mg/mL). Arginine 102-105 adrenoceptor beta 2 Homo sapiens 65-70 21385652-10 2011 There was also a linkage disequilibrium found between beta(2)-AR 16 (Arg/Arg) and beta(2)-AR 27 (Gln/Gln). Arginine 69-72 adrenoceptor beta 2 Homo sapiens 54-64 22713184-15 2011 The existence of genetic polymorphisms of ADRB2 gene, already described in the literature, show an increasing in bronchodilation response of Arg/Arg homozygotes when beta-adrenergic therapeutic is replaced for the anticholinergic one. Arginine 141-144 adrenoceptor beta 2 Homo sapiens 42-47 22713184-15 2011 The existence of genetic polymorphisms of ADRB2 gene, already described in the literature, show an increasing in bronchodilation response of Arg/Arg homozygotes when beta-adrenergic therapeutic is replaced for the anticholinergic one. Arginine 145-148 adrenoceptor beta 2 Homo sapiens 42-47 22048503-1 2011 BACKGROUND AND OBJECTIVES: Several polymorphisms of the beta2-adrenergic receptor (beta2-AR) gene have been identified, including the amino acid substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic acid (Glu) at codon 27. Arginine 163-171 adrenoceptor beta 2 Homo sapiens 56-81 22048503-1 2011 BACKGROUND AND OBJECTIVES: Several polymorphisms of the beta2-adrenergic receptor (beta2-AR) gene have been identified, including the amino acid substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic acid (Glu) at codon 27. Arginine 163-171 adrenoceptor beta 2 Homo sapiens 83-91 22048503-1 2011 BACKGROUND AND OBJECTIVES: Several polymorphisms of the beta2-adrenergic receptor (beta2-AR) gene have been identified, including the amino acid substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic acid (Glu) at codon 27. Arginine 173-176 adrenoceptor beta 2 Homo sapiens 56-81 22048503-1 2011 BACKGROUND AND OBJECTIVES: Several polymorphisms of the beta2-adrenergic receptor (beta2-AR) gene have been identified, including the amino acid substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic acid (Glu) at codon 27. Arginine 173-176 adrenoceptor beta 2 Homo sapiens 83-91 21613201-14 2011 In a multiple linear regression model (R2 = 63.6%; P = 0.03), neonatal ADRB2 genotypes (p.16Arg/Arg and p.27Gln/Glu) and lower neonatal birth weight predicted lower UA lactate concentrations. Arginine 92-95 adrenoceptor beta 2 Homo sapiens 71-76 21436355-1 2011 Arg/Arg homozygotes for the Gly16Arg polymorphism in the beta2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting beta2-agonists but no effect has been associated with long-acting beta2-agonists (LABAs). Arginine 0-3 adrenoceptor beta 2 Homo sapiens 57-77 21436355-1 2011 Arg/Arg homozygotes for the Gly16Arg polymorphism in the beta2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting beta2-agonists but no effect has been associated with long-acting beta2-agonists (LABAs). Arginine 0-3 adrenoceptor beta 2 Homo sapiens 84-89 21436355-1 2011 Arg/Arg homozygotes for the Gly16Arg polymorphism in the beta2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting beta2-agonists but no effect has been associated with long-acting beta2-agonists (LABAs). Arginine 4-7 adrenoceptor beta 2 Homo sapiens 57-77 21436355-1 2011 Arg/Arg homozygotes for the Gly16Arg polymorphism in the beta2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting beta2-agonists but no effect has been associated with long-acting beta2-agonists (LABAs). Arginine 4-7 adrenoceptor beta 2 Homo sapiens 84-89 21600547-9 2011 CONCLUSION: Homozygous beta2AR genotype encoding for Arg/Arg16 was associated with slower progress in active labor. Arginine 53-56 adrenoceptor beta 2 Homo sapiens 23-30 21572694-1 2011 BACKGROUND AND OBJECTIVES: Two polymorphisms of beta(2)-adrenergic receptor (beta(2)-AR) gene, namely the substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic (Glu) at codon 27, are linked with functional changes in the beta(2)-AR in the respiratory system even though they are not deemed to be susceptibility genes for asthma per se. Arginine 124-132 adrenoceptor beta 2 Homo sapiens 48-75 21572694-1 2011 BACKGROUND AND OBJECTIVES: Two polymorphisms of beta(2)-adrenergic receptor (beta(2)-AR) gene, namely the substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic (Glu) at codon 27, are linked with functional changes in the beta(2)-AR in the respiratory system even though they are not deemed to be susceptibility genes for asthma per se. Arginine 124-132 adrenoceptor beta 2 Homo sapiens 77-87 21572694-1 2011 BACKGROUND AND OBJECTIVES: Two polymorphisms of beta(2)-adrenergic receptor (beta(2)-AR) gene, namely the substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic (Glu) at codon 27, are linked with functional changes in the beta(2)-AR in the respiratory system even though they are not deemed to be susceptibility genes for asthma per se. Arginine 134-137 adrenoceptor beta 2 Homo sapiens 48-75 21572694-1 2011 BACKGROUND AND OBJECTIVES: Two polymorphisms of beta(2)-adrenergic receptor (beta(2)-AR) gene, namely the substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic (Glu) at codon 27, are linked with functional changes in the beta(2)-AR in the respiratory system even though they are not deemed to be susceptibility genes for asthma per se. Arginine 134-137 adrenoceptor beta 2 Homo sapiens 77-87 20883807-6 2011 While the clinical therapeutic application of airway biomarkers such as exhaled nitric oxide and beta(2)-adrenoreceptor Arg-16 polymorphism are still in their infancy, they have followed this common pathway of development, and now will require some years of application to demonstrate their true utility as predictive biomarkers of airway status and treatment response. Arginine 120-123 adrenoceptor beta 2 Homo sapiens 97-119 21385652-10 2011 There was also a linkage disequilibrium found between beta(2)-AR 16 (Arg/Arg) and beta(2)-AR 27 (Gln/Gln). Arginine 69-72 adrenoceptor beta 2 Homo sapiens 82-92 21385652-10 2011 There was also a linkage disequilibrium found between beta(2)-AR 16 (Arg/Arg) and beta(2)-AR 27 (Gln/Gln). Arginine 73-76 adrenoceptor beta 2 Homo sapiens 54-64 21385652-10 2011 There was also a linkage disequilibrium found between beta(2)-AR 16 (Arg/Arg) and beta(2)-AR 27 (Gln/Gln). Arginine 73-76 adrenoceptor beta 2 Homo sapiens 82-92 18983266-6 2009 Arg(333) and Lys(348) in the C-terminal tail of the beta2AR were identified as crucial determinants for Rab11 binding. Arginine 0-3 adrenoceptor beta 2 Homo sapiens 52-59 21038778-1 2010 The genetic polymorphisms at the 16th (Arg--> Gly) and 27th (Gln-->Glu) amino acid positions of the beta2-adrenergic receptor (ADRB2) may be linked to various asthma-related phenotypes. Arginine 39-42 adrenoceptor beta 2 Homo sapiens 106-131 22094842-5 2011 CART analysis showed that smoking parents who overate and carried the Arg allele, ADRB2 R16G, had an odds ratio (OR) of 11.7 (95% confidence interval (CI), 2.13-64.04) for obesity compared to non-smoking parents who had none of these factors. Arginine 70-73 adrenoceptor beta 2 Homo sapiens 82-87 21959333-4 2011 In analysis of the genotypes combination, only the carriers of both beta2AR Arg/Arg and UCP1 G/G genotypes had significantly higher waist to hip ratio (p=0.014). Arginine 76-79 adrenoceptor beta 2 Homo sapiens 68-75 21959333-4 2011 In analysis of the genotypes combination, only the carriers of both beta2AR Arg/Arg and UCP1 G/G genotypes had significantly higher waist to hip ratio (p=0.014). Arginine 80-83 adrenoceptor beta 2 Homo sapiens 68-75 19800676-4 2009 METHODS: Arg/Gly status at position 16 of ADRB2 was assessed in 1182 young asthmatic patients (age, 3-22 years) from Scotland. Arginine 9-12 adrenoceptor beta 2 Homo sapiens 42-47 19932356-1 2009 BACKGROUND: Some studies suggest that patients with asthma who are homozygous for arginine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less from treatment with longacting beta2 agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). Arginine 82-90 adrenoceptor beta 2 Homo sapiens 130-155 19932356-1 2009 BACKGROUND: Some studies suggest that patients with asthma who are homozygous for arginine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less from treatment with longacting beta2 agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). Arginine 161-164 adrenoceptor beta 2 Homo sapiens 130-155 19932356-1 2009 BACKGROUND: Some studies suggest that patients with asthma who are homozygous for arginine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less from treatment with longacting beta2 agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). Arginine 165-168 adrenoceptor beta 2 Homo sapiens 130-155 19373110-8 2009 RESULTS: The odds ratio for the presence of hypertension in individuals having the Gly/Gly genotype of ADRB2 compared with those having the other genotypes (Arg/Arg and Arg/Gly) was 2.87. Arginine 161-164 adrenoceptor beta 2 Homo sapiens 103-108 19373110-8 2009 RESULTS: The odds ratio for the presence of hypertension in individuals having the Gly/Gly genotype of ADRB2 compared with those having the other genotypes (Arg/Arg and Arg/Gly) was 2.87. Arginine 161-164 adrenoceptor beta 2 Homo sapiens 103-108 19430548-12 2009 CONCLUSION: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy. Arginine 40-43 adrenoceptor beta 2 Homo sapiens 72-77 19430548-12 2009 CONCLUSION: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy. Arginine 40-43 adrenoceptor beta 2 Homo sapiens 204-209 19430548-12 2009 CONCLUSION: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy. Arginine 44-47 adrenoceptor beta 2 Homo sapiens 72-77 19430548-12 2009 CONCLUSION: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy. Arginine 44-47 adrenoceptor beta 2 Homo sapiens 204-209 19461900-7 2009 Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the beta2-adrenergic receptor and those with a high percentage of neutrophils in sputum. Arginine 103-106 adrenoceptor beta 2 Homo sapiens 128-153 19461900-7 2009 Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the beta2-adrenergic receptor and those with a high percentage of neutrophils in sputum. Arginine 107-110 adrenoceptor beta 2 Homo sapiens 128-153 19441602-1 2009 BACKGROUND: Beta 2-Adrenergic receptor polymorphisms occurring at amino acid positions 16 (arginine/glycine) and 27 (glutamine/glutamic acid) are known to be functionally relevant. Arginine 91-99 adrenoceptor beta 2 Homo sapiens 12-38 19293197-5 2009 DNA was isolated from whole blood and beta2-AR gene polymorphisms Arg/Gly16 and Gln/Glu27 were determined using allele-specific polymerase chain reaction [PCR]. Arginine 66-69 adrenoceptor beta 2 Homo sapiens 38-46 18399855-9 2008 CONCLUSIONS: These findings indicate that the homozygous Arg/Arg genotype at amino acid 16 of the beta(2)-AR could affect bronchodilator response to tiotropium in patients with COPD with significant effects on health-related quality of life. Arginine 57-60 adrenoceptor beta 2 Homo sapiens 98-108 18841999-3 2008 To explore the roles of the two post-translational modifications, we mutated the three C-terminal lysines to arginines in the human beta 2-adrenergic receptor (beta 2AR) (K348/372/375R). Arginine 109-118 adrenoceptor beta 2 Homo sapiens 132-158 18841999-3 2008 To explore the roles of the two post-translational modifications, we mutated the three C-terminal lysines to arginines in the human beta 2-adrenergic receptor (beta 2AR) (K348/372/375R). Arginine 109-118 adrenoceptor beta 2 Homo sapiens 160-168 18430791-4 2008 Because of her asthma history, self-reported adherence, and race, she was tested for beta(2)-adrenoreceptor genotype, which revealed Arg/Arg. Arginine 133-136 adrenoceptor beta 2 Homo sapiens 85-107 18430791-4 2008 Because of her asthma history, self-reported adherence, and race, she was tested for beta(2)-adrenoreceptor genotype, which revealed Arg/Arg. Arginine 137-140 adrenoceptor beta 2 Homo sapiens 85-107 18714823-5 2008 beta2-AR genotypes and allele frequencies at amino acid positions 16 (beta2-AR-16: Arg-->Gly) and 27 (beta2-AR-27: Gln-->Glu) were identified by PCR-RFLP. Arginine 83-86 adrenoceptor beta 2 Homo sapiens 0-8 18399855-9 2008 CONCLUSIONS: These findings indicate that the homozygous Arg/Arg genotype at amino acid 16 of the beta(2)-AR could affect bronchodilator response to tiotropium in patients with COPD with significant effects on health-related quality of life. Arginine 61-64 adrenoceptor beta 2 Homo sapiens 98-108 19088492-7 2008 In contrast, female ADRB2 Arg/Arg homozygotes had increased pretreatment ACTH (F = 7.17, d.f. Arginine 26-29 adrenoceptor beta 2 Homo sapiens 20-25 18324973-4 2008 We found that the beta(2)AR arg(16)-->gly substitution and two non-coding ADCY6 polymorphisms were associated with elevated adhesion. Arginine 28-31 adrenoceptor beta 2 Homo sapiens 18-27 19088492-7 2008 In contrast, female ADRB2 Arg/Arg homozygotes had increased pretreatment ACTH (F = 7.17, d.f. Arginine 30-33 adrenoceptor beta 2 Homo sapiens 20-25 17925066-4 2007 Results from these studies demonstrate that patients with the Arg/Arg phenotype at the 16th amino acid position of the beta2-adrenergic receptor may experience worsening asthma outcomes after regular beta2-agonist use. Arginine 62-65 adrenoceptor beta 2 Homo sapiens 119-144 18156033-1 2007 BACKGROUND: New evidence has suggested that people with asthma who are homozygous for arginine at aminoacid 16 of the beta2-adrenergic receptor (ADRB2) might not benefit from longacting beta2-agonist therapy. Arginine 86-94 adrenoceptor beta 2 Homo sapiens 118-143 18156033-1 2007 BACKGROUND: New evidence has suggested that people with asthma who are homozygous for arginine at aminoacid 16 of the beta2-adrenergic receptor (ADRB2) might not benefit from longacting beta2-agonist therapy. Arginine 86-94 adrenoceptor beta 2 Homo sapiens 145-150 18035963-3 2007 Polymorphisms of the beta2 adrenoceptor (ADRB2), notably the variant associated with an arginine moiety at position 16 of the ADRB2 protein result in changes in in vitro receptor function. Arginine 88-96 adrenoceptor beta 2 Homo sapiens 21-39 18035963-3 2007 Polymorphisms of the beta2 adrenoceptor (ADRB2), notably the variant associated with an arginine moiety at position 16 of the ADRB2 protein result in changes in in vitro receptor function. Arginine 88-96 adrenoceptor beta 2 Homo sapiens 41-46 18035963-3 2007 Polymorphisms of the beta2 adrenoceptor (ADRB2), notably the variant associated with an arginine moiety at position 16 of the ADRB2 protein result in changes in in vitro receptor function. Arginine 88-96 adrenoceptor beta 2 Homo sapiens 126-131 17925066-4 2007 Results from these studies demonstrate that patients with the Arg/Arg phenotype at the 16th amino acid position of the beta2-adrenergic receptor may experience worsening asthma outcomes after regular beta2-agonist use. Arginine 66-69 adrenoceptor beta 2 Homo sapiens 119-144 17374341-3 2007 In 597 patients treated by a beta-blocker and followed for 3 years after a myocardial infarction or an acute coronary syndrome, the death rate was 5.4 times higher in homozygous Arg 16 and Gln 27 B2AR genotypes than in heterozygous or homozygous Gly 16 and Glu 27 B2AR genotypes. Arginine 178-181 adrenoceptor beta 2 Homo sapiens 264-268 17336757-0 2007 Arginine 16 glycine beta2-adrenoceptor polymorphism and cardiovascular structure and function in patients with heart failure. Arginine 0-8 adrenoceptor beta 2 Homo sapiens 20-38 17336757-2 2007 In healthy human beings, those who are homozygous for arginine (Arg) at amino acid 16 of the ADRB2 have reduced receptor function when compared with individuals homozygous for glycine (Gly) at this position. Arginine 54-62 adrenoceptor beta 2 Homo sapiens 93-98 17336757-2 2007 In healthy human beings, those who are homozygous for arginine (Arg) at amino acid 16 of the ADRB2 have reduced receptor function when compared with individuals homozygous for glycine (Gly) at this position. Arginine 64-67 adrenoceptor beta 2 Homo sapiens 93-98 17347382-2 2007 Previous research has suggested that subjects homozygous for arginine at amino acid 16 of the beta2AR (Arg16) may have attenuated receptor function relative to subjects homozygous for glycine at the same amino acid (Gly16). Arginine 61-69 adrenoceptor beta 2 Homo sapiens 94-101 17347382-8 2007 These data suggest that subjects homozygous for Arg at amino acid 16 of the beta2AR have a greater susceptibility for lung fluid accumulation relative to subjects homozygous for Gly at this position. Arginine 48-51 adrenoceptor beta 2 Homo sapiens 76-83 17150099-11 2006 In individuals that were UCP3 T-carriers and ADRB2-16 Arg-carriers the OR increased from 1 in the youngest to 10.84 (95% CI 4.54-25.85) in the oldest. Arginine 54-57 adrenoceptor beta 2 Homo sapiens 45-50 16873402-4 2006 beta(2)AR stimulation increased l-arginine transport, as did cyclic AMP elevation with either forskolin or dibutyryl cyclic AMP, and this increase was inhibitable by N-ethylmaleimide. Arginine 32-42 adrenoceptor beta 2 Homo sapiens 0-9 16873402-6 2006 beta(2)AR stimulation also caused a membrane hyperpolarization inhibitable by l-NAME, suggesting that the increase in l-arginine uptake occurred in response to NO-mediated hyperpolarization. Arginine 118-128 adrenoceptor beta 2 Homo sapiens 0-9 16873402-8 2006 These findings suggest that beta(2)AR-mediated NOS-3 activation in HUVEC is mediated through phosphorylation of NOS-3 on serine-1177 through both the PKA and the PI3K/Akt systems, and is sustained by an increase in l-arginine uptake resulting from NO-mediated membrane hyperpolarization. Arginine 215-225 adrenoceptor beta 2 Homo sapiens 28-37 17099033-4 2006 METHODS: We studied baseline PF according to genetic variations of the ADRB2 at amino acid 16 (ie, arginine [Arg] or glycine [Gly]) in 126 CHF patients (mean [+/- SEM] age, 56 +/- 1 years; left ventricular ejection fraction [LVEF], 29 +/- 1%; body mass index [BMI], 28 +/- 0.4 kg/m2) and in 100 healthy control subjects (mean age, 50 +/- 2 years; LVEF, 63 +/- 0.7%; BMI, 25 +/- 0.3 kg/m2). Arginine 99-107 adrenoceptor beta 2 Homo sapiens 71-76 17099033-4 2006 METHODS: We studied baseline PF according to genetic variations of the ADRB2 at amino acid 16 (ie, arginine [Arg] or glycine [Gly]) in 126 CHF patients (mean [+/- SEM] age, 56 +/- 1 years; left ventricular ejection fraction [LVEF], 29 +/- 1%; body mass index [BMI], 28 +/- 0.4 kg/m2) and in 100 healthy control subjects (mean age, 50 +/- 2 years; LVEF, 63 +/- 0.7%; BMI, 25 +/- 0.3 kg/m2). Arginine 109-112 adrenoceptor beta 2 Homo sapiens 71-76 17099033-8 2006 CONCLUSIONS: These data suggest that genetic variation of the ADRB2 is associated with differences in PF in CHF patients but not in healthy subjects, which may be related to an increased susceptibility of the homozygous Arg subjects to agonist-mediated desensitization of ADRB2s in the lungs, or related to an influence of this polymorphism on cardiac diastolic properties. Arginine 220-223 adrenoceptor beta 2 Homo sapiens 62-67 17099033-8 2006 CONCLUSIONS: These data suggest that genetic variation of the ADRB2 is associated with differences in PF in CHF patients but not in healthy subjects, which may be related to an increased susceptibility of the homozygous Arg subjects to agonist-mediated desensitization of ADRB2s in the lungs, or related to an influence of this polymorphism on cardiac diastolic properties. Arginine 220-223 adrenoceptor beta 2 Homo sapiens 272-277 16772309-1 2006 BACKGROUND: The homozygous presence of the arginine-16 variant of the beta(2) adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting beta(2) agonists in asthmatic adults compared with the homozygous glycine-16 genotype. Arginine 43-51 adrenoceptor beta 2 Homo sapiens 70-90 16772309-1 2006 BACKGROUND: The homozygous presence of the arginine-16 variant of the beta(2) adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting beta(2) agonists in asthmatic adults compared with the homozygous glycine-16 genotype. Arginine 43-51 adrenoceptor beta 2 Homo sapiens 96-101 16772309-7 2006 CONCLUSIONS: The arginine-16 genotype of ADRB2 predisposes to exacerbations in asthmatic children and young adults, particularly in those exposed to regular salmeterol. Arginine 17-25 adrenoceptor beta 2 Homo sapiens 41-46 16339181-1 2006 In humans, subjects homozygous for arginine (ArgArg) at codon 16 of the beta2-adrenergic receptor (beta2AR) have been shown to have greater agonist-mediated desensitization than subjects homozygous for glycine (GlyGly). Arginine 35-43 adrenoceptor beta 2 Homo sapiens 72-97 16672841-1 2006 INTRODUCTION: Several common polymorphisms of the beta2 adrenergic (ADRB2) have been described including a Glycine (Gly) for arginine (Arg) substitution at amino acid 16. Arginine 125-133 adrenoceptor beta 2 Homo sapiens 68-73 16672841-1 2006 INTRODUCTION: Several common polymorphisms of the beta2 adrenergic (ADRB2) have been described including a Glycine (Gly) for arginine (Arg) substitution at amino acid 16. Arginine 135-138 adrenoceptor beta 2 Homo sapiens 68-73 16683069-2 2006 Normotensive adults homozygous for glycine (Gly) of the Arg16/Gly beta2-adrenergic receptor polymorphism have a greater forearm beta2-receptor mediated vasodilation and a higher cardiac output response to isometric handgrip than arginine (Arg) homozygotes. Arginine 229-237 adrenoceptor beta 2 Homo sapiens 66-91 16683069-2 2006 Normotensive adults homozygous for glycine (Gly) of the Arg16/Gly beta2-adrenergic receptor polymorphism have a greater forearm beta2-receptor mediated vasodilation and a higher cardiac output response to isometric handgrip than arginine (Arg) homozygotes. Arginine 56-59 adrenoceptor beta 2 Homo sapiens 66-91 16322642-1 2006 RATIONALE: Several studies suggest that patients with asthma who are homozygous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-acting beta-agonists. Arginine 84-92 adrenoceptor beta 2 Homo sapiens 121-146 16339181-1 2006 In humans, subjects homozygous for arginine (ArgArg) at codon 16 of the beta2-adrenergic receptor (beta2AR) have been shown to have greater agonist-mediated desensitization than subjects homozygous for glycine (GlyGly). Arginine 35-43 adrenoceptor beta 2 Homo sapiens 99-106 16339181-8 2006 These data suggest that subjects homozygous for Arg at codon 16 of the beta2AR have reduced and MAP at rest that persist during exercise with no evidence for differential changes over the course of exercise despite large changes in catecholamines. Arginine 48-51 adrenoceptor beta 2 Homo sapiens 71-78 16357581-3 2006 RECENT FINDINGS: A genotype-stratified study revealed that greater bronchoprotective effect of anticholinergic agents was observed in asthmatic patients with the Arg/Arg genotype of the beta2-adrenergic receptor. Arginine 162-165 adrenoceptor beta 2 Homo sapiens 186-211 16357581-3 2006 RECENT FINDINGS: A genotype-stratified study revealed that greater bronchoprotective effect of anticholinergic agents was observed in asthmatic patients with the Arg/Arg genotype of the beta2-adrenergic receptor. Arginine 166-169 adrenoceptor beta 2 Homo sapiens 186-211 16369119-1 2006 BACKGROUND: beta(2)-Adrenergic receptor (beta(2)-AR) polymorphisms occurring at amino acid position 16 (Arg-Gly) and 27 (Gln-Glu) are known to be functionally relevant and also disease-modifying in subjects with asthma. Arginine 104-107 adrenoceptor beta 2 Homo sapiens 12-39 16369119-1 2006 BACKGROUND: beta(2)-Adrenergic receptor (beta(2)-AR) polymorphisms occurring at amino acid position 16 (Arg-Gly) and 27 (Gln-Glu) are known to be functionally relevant and also disease-modifying in subjects with asthma. Arginine 104-107 adrenoceptor beta 2 Homo sapiens 41-51 16369120-1 2006 BACKGROUND: As a result of the finding that the mutation of Arg into Gly at beta(2)-adrenergic receptor (beta(2)-AR)16 loci could promote the downregulation effect triggered by the beta(2)-agonist, it was supposed that Gly16 might be associated with the downregulation of beta(2)-AR in patients with nocturnal asthma. Arginine 60-63 adrenoceptor beta 2 Homo sapiens 105-115 16369120-1 2006 BACKGROUND: As a result of the finding that the mutation of Arg into Gly at beta(2)-adrenergic receptor (beta(2)-AR)16 loci could promote the downregulation effect triggered by the beta(2)-agonist, it was supposed that Gly16 might be associated with the downregulation of beta(2)-AR in patients with nocturnal asthma. Arginine 60-63 adrenoceptor beta 2 Homo sapiens 272-282 15334382-1 2004 We examined the effects of combined genotypes of the beta(2)-adrenergic receptor (AR) Arg(16)-Gly and beta(3)-AR Trp(64)-Arg polymorphisms on longitudinal serum total (T-C) and low-density lipoprotein cholesterol (LDL-C) profiles in 1,198 subjects examined multiple times (6,488 observations) from 1973 to 1996 in the Bogalusa Heart Study, at ages from 4.5 to 38 years. Arginine 86-89 adrenoceptor beta 2 Homo sapiens 82-84 15500895-2 2004 Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor. Arginine 137-145 adrenoceptor beta 2 Homo sapiens 219-244 15500895-2 2004 Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor. Arginine 147-150 adrenoceptor beta 2 Homo sapiens 219-244 15987731-1 2005 A number of studies have investigated two common polymorphisms in the beta(2)-adrenoceptor gene, Arg/Gly16 and Gln/Glu27, in relation to asthma susceptibility. Arginine 97-100 adrenoceptor beta 2 Homo sapiens 70-90 15946904-3 2005 RESULTS: Three common polymorphisms were abundant in at least one allele in beta2AR resulting in a cysteine to arginine in the 5" promoter region (72% of patients), an arginine to glycine at amino acid-16 (Gly16; 86%), and a glutamine to glutamic acid at amino acid-27 (Glu27; 66%), a frequency that was no different to the normal Caucasian population. Arginine 111-119 adrenoceptor beta 2 Homo sapiens 76-83 15334382-2 2004 Within 5-year age groups, T-C was significantly (P <.05) higher in beta(2)-AR Arg(16)/Arg(16) homozygotes than in Gly(16) carriers among those 4 to 8 (171.4 +/- 30.0 v 161.5 +/- 27.7 mg/dL), 9 to 13 (167.7 +/- 28.6 v 162.4 +/- 27.4 mg/dL), and 14 to 18 (158.8 +/- 29.6 v 154.7 +/- 27.5 mg/dL) years of age, but not in those 19 to 23, 24 to 28, 29 to 33, or 34 to 38 years of age. Arginine 81-84 adrenoceptor beta 2 Homo sapiens 70-80 15334382-8 2004 Our findings suggest that the beta(2)-AR Arg(16)-Gly genotype influences T-C and LDL-C levels in an age-specific manner, that it may interact with beta(3)-AR Trp(64)-Arg genotypes to influence longitudinal T-C and LDL-C profiles, and that the effect of combined beta(2)/beta(3)-AR genotypes on T-C and LDL-C profiles may differ among race/sex groups. Arginine 41-44 adrenoceptor beta 2 Homo sapiens 30-40 15493717-7 2004 CONCLUSION: At codon 16 of the beta2-AR gene, maternal Arg-16 homozygosity protects against, and Gly-16 predisposes to spontaneous preterm birth. Arginine 55-58 adrenoceptor beta 2 Homo sapiens 31-39 15069780-1 2004 It has been suggested that the Arg 16/Gly 16 allele at codon 16 of beta 2-adrenoceptor polymorphism plays a role in down-regulating the stimulus of bronchodilatation caused by beta 2-agonists. Arginine 31-34 adrenoceptor beta 2 Homo sapiens 67-86 12442007-8 2002 RESULTS: The frequency of the Arg/Arg genotype of the ADRB2 gene and the TT genotype of the IL-4 gene were significantly higher in patients with interstitial cystitis than in controls. Arginine 30-33 adrenoceptor beta 2 Homo sapiens 54-59 13680034-1 2003 OBJECTIVE: It has been shown that arginine to glycine (Arg16Gly), glutamine to glutamic acid (Gln27Glu) and threonine to isoleucine (Thr164Ile) exchanges in codons 16, 27 and 164, respectively, of the beta 2-adrenergic receptor (B2AR) gene significantly alter receptor function. Arginine 34-42 adrenoceptor beta 2 Homo sapiens 201-227 13680034-1 2003 OBJECTIVE: It has been shown that arginine to glycine (Arg16Gly), glutamine to glutamic acid (Gln27Glu) and threonine to isoleucine (Thr164Ile) exchanges in codons 16, 27 and 164, respectively, of the beta 2-adrenergic receptor (B2AR) gene significantly alter receptor function. Arginine 34-42 adrenoceptor beta 2 Homo sapiens 229-233 14557466-2 2003 The goal of the present study was to assess the association between the Gly(16)-->Arg(16) and Gln(27)-->Glu(27) polymorphisms of the beta(2)-adrenergic receptor and metabolic syndrome. Arginine 85-88 adrenoceptor beta 2 Homo sapiens 139-166 14557466-11 2003 In conclusion, these data suggest that the Arg(16) and Gln(27) variants of the beta(2)-adrenergic receptor gene contribute to metabolic syndrome susceptibility in men. Arginine 43-46 adrenoceptor beta 2 Homo sapiens 79-106 14650112-1 2003 BACKGROUND: It has been argued that arginine replacement in locus 16 (Arg16) of beta 2 adrenergic receptor with glycin (Gly16) increases asthma severity, while glutamin replacement in locus 27 (Gln27) with glutamic acid (Glu27) decreases it. Arginine 36-44 adrenoceptor beta 2 Homo sapiens 80-106 12464940-5 2002 Individuals homozygous for arginine at locus 16 of the beta(2)-adrenergic receptor gene have a decline in pulmonary function during beta(2)-agonist use, and they are at greater risk of asthma exacerbations during beta(2)-agonist therapy than patients with other genotypes. Arginine 27-35 adrenoceptor beta 2 Homo sapiens 55-82 12442007-8 2002 RESULTS: The frequency of the Arg/Arg genotype of the ADRB2 gene and the TT genotype of the IL-4 gene were significantly higher in patients with interstitial cystitis than in controls. Arginine 34-37 adrenoceptor beta 2 Homo sapiens 54-59 11306963-4 2001 RESULTS: During the 16-week treatment period, patients homozygous for arginine (Arg/Arg) at beta(2)-AR-16 who used albuterol regularly had a small decline in morning peak expiratory flow (AM PEF). Arginine 70-78 adrenoceptor beta 2 Homo sapiens 92-102 11412813-3 2001 The B2AR polymorphism of interest involves a single nucleotide change from A to G, resulting in an amino acid change from Arginine (Arg) to Glycine (Gly). Arginine 122-130 adrenoceptor beta 2 Homo sapiens 4-8 11412813-3 2001 The B2AR polymorphism of interest involves a single nucleotide change from A to G, resulting in an amino acid change from Arginine (Arg) to Glycine (Gly). Arginine 122-125 adrenoceptor beta 2 Homo sapiens 4-8 11434877-5 2001 RESULTS: Twenty-five (12.4%) breast cancer patients and 32 (17.6%) control individuals were found to bear a glutamic acid (Glu) allele for the ADRB2 gene (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.38-1.18), and 60 (30.0%) breast cancer patients and 61 (33.5%) control individuals were found to bear an Arg allele for the ADRB3 gene (OR 0.85, 95% CI 0.55-1.31). Arginine 313-316 adrenoceptor beta 2 Homo sapiens 143-148 14526489-8 2003 The homozygous glycine-16 (Arg-->Gly) variant of the beta 2-adrenoceptor is known to predispose to agonist-induced down-regulation and desensitization, and may play a role in the pathogenesis of asthma severity. Arginine 27-30 adrenoceptor beta 2 Homo sapiens 56-75 11777907-2 2002 The interaction of beta(2)-adaptin with beta-arrestin involves critical arginine residues in the C-terminal domain of beta-arrestin and plays an important role in initiating clathrin-mediated endocytosis of the beta(2)-adrenergic receptor (beta(2)AR) (Laporte, S. A., Oakley, R. H., Holt, J. Arginine 72-80 adrenoceptor beta 2 Homo sapiens 211-238 11777907-2 2002 The interaction of beta(2)-adaptin with beta-arrestin involves critical arginine residues in the C-terminal domain of beta-arrestin and plays an important role in initiating clathrin-mediated endocytosis of the beta(2)-adrenergic receptor (beta(2)AR) (Laporte, S. A., Oakley, R. H., Holt, J. Arginine 72-80 adrenoceptor beta 2 Homo sapiens 240-249 11775126-0 2001 The glycine allele of a glycine/arginine polymorphism in the beta2-adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin. Arginine 32-40 adrenoceptor beta 2 Homo sapiens 61-86 11811387-8 2001 Beta2-adrenoceptor stimulation increases forearm blood flow (FBF) by activating the L-arginine/NO pathway but nebivolol lacks direct beta2-adrenoceptor agonist activity. Arginine 84-94 adrenoceptor beta 2 Homo sapiens 0-18 11306963-4 2001 RESULTS: During the 16-week treatment period, patients homozygous for arginine (Arg/Arg) at beta(2)-AR-16 who used albuterol regularly had a small decline in morning peak expiratory flow (AM PEF). Arginine 80-83 adrenoceptor beta 2 Homo sapiens 92-102 11306963-4 2001 RESULTS: During the 16-week treatment period, patients homozygous for arginine (Arg/Arg) at beta(2)-AR-16 who used albuterol regularly had a small decline in morning peak expiratory flow (AM PEF). Arginine 84-87 adrenoceptor beta 2 Homo sapiens 92-102 11778498-3 2000 RESULTS: (1) The distribution frequency of genotype beta 2-AR 16 loci: Arg/Arg genotype accounts for 13%, Arg/Gly 76% and Gly/Gly 11%. Arginine 71-74 adrenoceptor beta 2 Homo sapiens 52-61 11778498-3 2000 RESULTS: (1) The distribution frequency of genotype beta 2-AR 16 loci: Arg/Arg genotype accounts for 13%, Arg/Gly 76% and Gly/Gly 11%. Arginine 75-78 adrenoceptor beta 2 Homo sapiens 52-61 11778498-3 2000 RESULTS: (1) The distribution frequency of genotype beta 2-AR 16 loci: Arg/Arg genotype accounts for 13%, Arg/Gly 76% and Gly/Gly 11%. Arginine 75-78 adrenoceptor beta 2 Homo sapiens 52-61 11778498-6 2000 (2) The frequency of genotype beta 2-AR 16 loci in asthmatics: Arg/Arg genotype accounts for 24%, Arg/Gly 45% and Gly/Gly 31%. Arginine 63-66 adrenoceptor beta 2 Homo sapiens 30-39 11778498-6 2000 (2) The frequency of genotype beta 2-AR 16 loci in asthmatics: Arg/Arg genotype accounts for 24%, Arg/Gly 45% and Gly/Gly 31%. Arginine 67-70 adrenoceptor beta 2 Homo sapiens 30-39 11778498-6 2000 (2) The frequency of genotype beta 2-AR 16 loci in asthmatics: Arg/Arg genotype accounts for 24%, Arg/Gly 45% and Gly/Gly 31%. Arginine 67-70 adrenoceptor beta 2 Homo sapiens 30-39 9826914-9 1998 Arginine could also be substituted by other amino acids without loss of coupling to Gs demonstrating an unexpected lack of selectivity in the human beta 2-adrenergic receptor protein, and ruling out a requirement for the side chain of arginine in signalling to G proteins. Arginine 0-8 adrenoceptor beta 2 Homo sapiens 148-174 10323412-10 1999 The exchange at -47 may alter the expression level of the beta2-adrenergic receptor gene, because the nucleotide substitution at -47 results in a Cys-->Arg exchange at the C terminal of the leader peptide. Arginine 152-155 adrenoceptor beta 2 Homo sapiens 58-83 9835617-8 1998 In human airway smooth muscle cells that natively express beta2AR, receptor expression was approximately twofold higher in those bearing the Cys versus the Arg polymorphism, confirming the phenotype in a relevant cell type. Arginine 156-159 adrenoceptor beta 2 Homo sapiens 58-65 24992184-11 2014 CONCLUSIONS: This meta-analysis implied that the beta2-adrenoceptor Arg/Gly16 polymorphism was likely to contribute to asthma risk in Asian population. Arginine 68-71 adrenoceptor beta 2 Homo sapiens 49-67